$60 Million to Transition to Clinical Stage

Superluminal Medicines closed an oversubscribed Series B round of $60 million on September 3, 2026. The round was led by BVF Partners, with new participation from Deep Track Capital and Perceptive Advisors, and follow-on support from RA Capital Management, Insight Partners, NVentures, Catalio Capital Management, and Eli Lilly and Company (LLY). The funds will be used to initiate a Phase 1 clinical trial for its lead candidate targeting rare genetic obesity and hypothalamic obesity by the end of 2026, and to expand its endocrine and cardio-metabolic disease pipeline. The transaction, supported by institutional investors, covers the costs of toxicity, manufacturing, and early human safety required for the transition from a discovery platform company to a clinical-stage biotech.

Oral MC4R Agonist Offers Dosing Convenience Differentiation

The lead candidate, an unnamed oral small-molecule selective biased melanocortin-4 receptor (MC4R) agonist, is currently in the investigational new drug (IND) application preparation stage, with a planned Phase 1 trial initiation by the end of 2026. MC4R is a clinically validated target regulating appetite and energy homeostasis, and biased signaling is designed to enhance desired receptor signaling to improve the balance between efficacy and tolerability. Superluminal optimized the structure and druggability of challenging G protein-coupled receptors (GPCRs) using its Hyperloop platform, which combines structural biology with artificial intelligence and machine learning. The oral formulation differentiates it from existing injectable therapies requiring daily administration, though real-world selectivity and clinical benefit must be validated in upcoming human trials.

Imcivree Validates Market and Intensifies Competition

The direct comparator is Rhythm Pharmaceuticals (RYTM)'s marketed MC4R agonist Imcivree (setmelanotide), a daily subcutaneous injectable targeting MC4R. The FDA approved it on November 27, 2020, for POMC, PCSK1, and LEPR deficiency obesity, expanded its indication to Bardet-Biedl syndrome on June 16, 2022, and approved it for acquired hypothalamic obesity on March 19, 2026. The EMA granted its first EU marketing authorization on July 16, 2021, following a positive opinion from the CHMP on May 20, 2021. Rhythm is also developing a weekly injectable RM-718 and an oral MC4R agonist bivamelagon, meaning Superluminal must demonstrate more than just oral convenience in terms of efficacy and safety.

Potential Expansion from Rare to Broad Obesity

The commercial potential of the rare obesity market is evidenced by Imcivree's estimated global net product sales of approximately $194 million in 2025 and $71.3 million in Q2 2026. Acquired hypothalamic obesity is a rare disease market in the U.S. with approximately 10,000 patients, where genetic testing and access to specialty centers are key to prescription expansion. In general obesity, Zepbound (tirzepatide)'s dual GIP-GLP-1 activity and Wegovy (semaglutide)'s GLP-1 activity form the standard competitive axis, but Superluminal's candidate targets the MC4R pathway to pursue both monotherapy in rare diseases and potential combination with GLP-1 agents. This fundraising is significant not for market size alone, but for the capital allocation toward a differentiated strategy combining an oral small molecule with precise signaling in a validated target.